Tirzepatide and intracranial hypertension are being studied together in the TIIHT trial at Duke University. The question is whether tirzepatide changes pressure inside the skull in people with idiopathic intracranial hypertension (IIH). The study design is not a finding that tirzepatide is effective for this condition.

Tirzepatide intracranial hypertension trial: TIIHT

The Phase IV, randomised, double-blind, placebo-controlled trial was listed as recruiting in the ClinicalTrials.gov record retrieved on 8 September 2026 to investigate the impact of tirzepatide on intracranial pressure (ICP) in individuals diagnosed with IIH. The study is conducted at a single centre by Duke University in collaboration with Eli Lilly and Company.

The trial aims to enrol approximately 60 participants aged between 18 and 60 years with a body mass index (BMI) of 30 kg/m2 or higher. Participants will be randomly assigned in a 1:1 ratio to receive either tirzepatide or a placebo over a 12-month period, with doses escalating gradually according to a defined schedule.

Intracranial pressure and vision: what the study measures

The primary outcome measure is the change in intracranial pressure assessed through lumbar puncture. Secondary outcomes include changes in retinal nerve fibre layer thickness measured by optical coherence tomography, alterations in papilledema grade via fundus photography, and visual field changes evaluated by perimetric mean deviation.

Statistical analysis will employ analysis of covariance (ANCOVA) to compare changes between the treatment and placebo groups, adjusting for baseline ICP values. The study is designed to maintain quadruple masking, ensuring that participants, care providers, investigators, and outcome assessors remain unaware of group assignments to reduce bias.

Eligibility and Exclusions

Eligible participants must exhibit clinical signs of raised intracranial pressure without secondary causes, be alert and able to consent, and meet specific ophthalmological and neurological criteria. Exclusion criteria include previous bariatric surgery, use of other GLP-1 agonists or anti-obesity medications, certain medical histories such as pancreatitis or thyroid cancer risk, pregnancy, and other conditions that may confound results.

Context and Considerations

The registered trial is NCT07191873. “Phase IV” does not mean tirzepatide is approved specifically for IIH; this study is investigating that use. It is essential to note that findings from this study are pending, and no clinical recommendations or treatment claims can be made at this stage.

Research-use disclaimer: This article is based on clinical trial information and is intended for educational purposes only. It does not provide medical advice, prescribing guidance, or treatment recommendations.

Related reading

Explore reading an early-phase trial, GLP-1 research context.

Sources

ClinicalTrials.gov: NCT07191873 — https://clinicaltrials.gov/study/NCT07191873

Duke Health: TIIHT study — https://duke-research.dukehealth.org/studies/pro00117470